LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Two Immunoassays Compared for Determination of Serum Vitamin D

By LabMedica International staff writers
Posted on 06 Jul 2021
Print article
Image: The IDS-iSYS Multi-Discipline Automated System Analyzer (Photo courtesy of Immunodiagnostic Systems)
Image: The IDS-iSYS Multi-Discipline Automated System Analyzer (Photo courtesy of Immunodiagnostic Systems)
Vitamin D is a fat-soluble steroid prohormone that is generated mainly in the skin by photochemical conversion of 7-dehydrocholesterol. 25-hydroxyvitamin D (25(OH)D) is its main storage form and is present in blood at very high concentration with respect to the active form 1,25-dihydroxyvitamin D.

The difficulties in the determination of 25(OH)D are related to its fat soluble nature, as well as its strong binding to the vitamin D binding protein (VDBP) and to serum albumin. On the other hand, although it would be appropriate for the different immunoassays to detect vitamin D2 and D3 in equimolar form, this is not usually fulfilled.

Clinical Biochemists at the Hospital Universitario Miguel Servet (Zaragoza, Spain) carried out a transversal descriptive observational study on a total of 184 individuals. The median age of the total of patients was 61 years old, with a minimum of 1 year and a maximum of 92. There were 31.5% men and 68.5% women. The samples came from both healthy patients and patients with various pathologies as bone, kidney, thyroid, cardiovascular, immune, neurological diseases and cancer.

The concentration of 25(OH)D was measured, as routine health analysis, by the automated IDS-iSYS 25VitD assay in an IDS-iSYS Multi-Discipline Automated System Analyzer (Vitro, Immunodiagnostic Systems Holdings PLC, Boldon Colliery, UK), which uses a chemiluminescence technology, which is fully automated. The same samples were processed by the Alinity i 25-OH Vitamin D assay in an Alinity i automated Analyzer (Abbott, Abbott Park, IL, USA), which is a one-step delayed-action immunoassay using chemiluminescent microparticles immunoassay (CMIA) technology.

The scientists reported that of the total patients, 52.7% received vitamin D supplements. The correlation coefficient of agreement for general group, supplementation group and group without supplementation was 0.92, 0.91 and 0.89, respectively. In all of them, a kappa index>0.75 was obtained. The mean value of the bias was higher for the supplemented group (−20.4 nmol/L) than for the group without treatment (−4.9 nmol/L). Graphically, a greater concordance between both assays was observed when patients receiving vitamin D supplements were excluded. The team observed lower concentrations of 25(OH)D in the IDS-iSYS 25 VitD assay when compared to the results obtained with the Alinity i 25-OH Vitamin D assay.

The authors concluded that the assays evaluated were not comparable to each other. Despite this, they show an excellent concordance in the evaluation of the vitamin D status. The study was published on June 23, 2021 in the journal Practical Laboratory Medicine.

Related Links:
Hospital Universitario Miguel Servet
Immunodiagnostic Systems Holdings PLC
Abbott


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.